The FDA has approved a subcutaneous dose for initiation of lecanemab treatment in adults with Alzheimer’s disease, according ...

Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according ...

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a ...

Once-weekly subcutaneous initiation dosing offers an at-home alternative for adults with MCI or mild dementia due to Alzheimer’s disease, potentially reducing infusion-center dependence and visit ...

A new under‑the‑skin version of isatuximab is now approved, giving multiple myeloma patients a much faster and more ...

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose ...

High cholesterol despite taking statins? Cardiologist Dr Naveen Bhamri explains who may benefit from cholesterol-lowering injections and how they work.

Approval was supported by IRAKLIA Phase III non-inferiority data comparing on-body injector subcutaneous isatuximab to weight-based IV, both combined with pomalidomide and dexamethasone in R/R myeloma ...

Eisai and Biogen have announced that the U.S. Food and Drug Administration has approved a supplemental biologics licence application for a once weekly subcutaneous initiation dose ...

The Trump administration is closing a loophole that drugmakers could use to avoid negotiations when they add active ...

Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...